Levetiracetam Injection
Product Images NDC 43598-637

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 43598-637). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Dr.reddy's Laboratories Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1000carton (1000carton)

Packaging label for Levetiracetam 0.75% Sodium Chloride Injection, with a strength of 1,000 mg/100 mL (10 mg/mL) in injection form for intravenous use. The label indicates it contains 10 single-dose bags and is manufactured by Dr. Reddy's Laboratories Inc. The label includes directions for use, cautionary statements, and storage recommendations.*

FDA Label Image

1500 Carton (1500 Carton)

Packaging label for Levetiracetam Injection at 15 mg/mL strength, specifically Levetiracetam in 0.54% Sodium Chloride Injection, with a concentration of 1,500 mg/100 mL for intravenous infusion. The label includes product details, dosing instructions, manufacturer Dr. Reddy's Laboratories Inc., NDC 43598-637-10, and storage recommendations. The label is printed in blue and black text on a white background.*

FDA Label Image

500carton (500carton)

Packaging label for Levetiracetam in 0.82% Sodium Chloride Injection, 500 mg/100 mL (5 mg/mL) intravenous infusion solution by Dr. Reddy's Laboratories Inc. The carton contains 10 single-dose bags. The label includes dosage instructions, storage conditions, cautions, and NDC 43598-635-10.*

FDA Label Image

Figure1 (Figure1)

A bar chart comparing the percentage of patients responding to different treatments: Placebo, Levetiracetam 1000 mg/day, and Levetiracetam 3000 mg/day. The vertical axis represents patient response percentages, with the placebo group at 7.4%, Levetiracetam 1000 mg/day group at 37.1%, and Levetiracetam 3000 mg/day group at 39.6%.*

FDA Label Image

Figure2 (Figure2)

A bar chart comparing the percentage of patients across three groups: Placebo (N=111), Levetiracetam 1000 mg/day (N=106), and Levetiracetam 2000 mg/day (N=105). The percentages depicted are approximately 6.3% for placebo, 20.8% for 1000 mg/day, and 35.2% for 2000 mg/day, with asterisks indicating statistical significance in the Levetiracetam groups.*

FDA Label Image

Figure3 (Figure3)

A bar chart comparing the percentage of patients between Placebo and Levetiracetam 3000 mg/day groups. The y-axis represents the percentage of patients from 0% to 45%. The Placebo group (N=104) shows 14.4%, while the Levetiracetam group (N=180) shows 39.4%, marked with an asterisk above the bar.*

FDA Label Image

Figure4 (Figure4)

A bar chart comparing the percentage of patients between two groups: Placebo (N=84) and Levetiracetam (N=79). The vertical axis represents the percentage of patients ranging from 0% to 100%. The Placebo group shows 45.2% and the Levetiracetam group shows 72.2%.*

FDA Label Image

Structure (Structure)

Chemical structure diagram of the active ingredient Levetiracetam, showing its molecular arrangement of atoms including a pyrrolidone ring and attached functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.